Objective - This study aims to improve the economic knowledge of major depression. It reports the investigation methodology and some preliminary indications on direct and indirect costs associated to this illness. Setting - Centro Psicosociale (CPS) USSL 72, Magenta (Mi) Italy. Design - We enrolled 10 patients (7F and 3M) with age between 34 and 65 (average 49.2 + 10.2 SD) at the first contact with CPS for an episode of major depression and we followed them up for 3 months. Main Measure Outcomes - At each visit we perform a clinical evaluation (HRS-D, CGI, DOTES) and we administered an interview to collect data in order to quantify social costs (direct and indirect) related to the observation period. Results - At the end of the 3 month period, all patients showed an improvement of the simptomatolgy as expressed by HRS-D (final score at least 50% below the initial one). Our accounting model estimated that the full cost of a psychiatric visit (on average lasting 47.8 minutes) is 107.537 Italian Liras. For the 10 patients under observation direct costs amounted to 9.402.000 It. Liras; psychiatric visits represented 70% of these costs. According to a conservative approach, indirect costs (value of labor time lost) amounted to 13.254.000 It. Liras if patients and relatives are considered and to 11.044.000 It. Liras if only patients time is evaluated. Conclusion - The paper presents a methodological proposal aimed to assess social costs of major depression. It also reports a first attempt to measure these costs in a prospective study performed in a public psychiatric centre. Our results have to be considered in the light of the limited sample of patients under observation and have to be regarded as strictly dependent on the specific context both in terms of the organizational settings and the characteristics of patients.

Objective - To consider the main problems associated with care and treatment of patients with diagnosis of schizophrenia in the light of the more recent literature of the economic aspects of this pathology. Method - An analysis of the literature related to the social costs of schizophrenia, the economic analysis of different health-care models, and the evaluation of the costs of antipsychotic treatments has been carried out. Results - Schizophrenia is a pathology creating huge social costs. The health costs associated with the care of schizophrenia take up a significant amount of the resources of healthcare systems in the principal industrialised countries. Indirect costs, due mainly to the patients' exclusion from work, exceed the direct costs of treatment. In those countries where community care has been supported by a real organisational effort to create community and residential services, it has proved to be a cost-effective solution compared with psychiatric hospital-based care and provides patients and family members with better results. The introduction of new antipsychotic drugs and the development of psychosocial support could represent the means of encouraging new healthcare strategies. Conclusions - From an economic perspective, the organisation, technological means, and strategies which would allow the available resources to be invested in a rational way must be considered. Consideration of these issues appears to be unavoidable today, not only for the administrators and the policy makers but also for mental health service professionals.